Zhenyi Medical Announces NeoBlazar®: China's First Transcatheter Tricuspid Valve Edge-to-Edge Repair System
Currently, a contradiction has arisen between the extremely limited supply of surgical procedures and the massive treatment demand, which is hundreds of times greater.Tricuspid Valve Interventional Therapya strong imperative need, for patients with surgical contraindications,Interventional TherapyIt is the last and only treatment option to save or prolong their lives.Transcatheter Tricuspid Valve RepairNo thoracotomy, no cardiac arrest, and no cardiopulmonary bypass are required, significantly reducing surgical trauma and offering a chance of survival to patients with multiple complications, high risk, or contraindications.
Jiangsu Zhenyi Medical Technology Co., Ltd.(hereinafter referred to as "Zhenyi Medical") independently developed“NeoBlazar® Transcatheter Tricuspid Valve Edge-to-Edge Repair System”, for edge-to-edge repair of tricuspid regurgitation in patients, only a small incision on the inner thigh is required to deliver the device to the site of the tricuspid valve lesion for treatment. Currently, clinically experienced expert physicians canWithin 60 minutesFollowing the procedure, most patients can have their tubes removed on the same day and begin walking the next day.
On Monday, August 26, at 19:30, the 88th edition of VCBeat New Product Review will feature Wang Yan, President of Xiamen University Affiliated Cardiovascular Hospital; Wei Yongqiang, Chief Technology Officer of Zhenyi Medical; and Xu Shuhuan, Marketing Director of Zhenyi Medical, who will present“China’s First Transcatheter Tricuspid Valve Edge-to-Edge Repair System—NeoBlazar®”Product Promotion.
NeoBlazar® Transcatheter Tricuspid Valve Edge-to-Edge Repair System
NeoBlazar®is a product independently developed by Zhenyi MedicalTranscatheter Tricuspid Valve Edge-to-Edge Repair System, the product boasts exceptional catheter steerability and superior device stability and maneuverability, outperforming international competitors while better aligning with the disease characteristics of Chinese patients and physicians’ usage preferences. To date, the NeoBlazar® system has been clinicallyAll participants have been enrolled and are currently under follow-up., no perioperative deaths occurred with the product, and the immediate surgical success rate100%, the subjects' cardiac function significantly improved postoperatively, earning consistent acclaim from clinicians and industry peers.The product has currently passed the NMPA’s Special Review for Innovative Medical Devices. It is the first and, to date, the only transcatheter edge-to-edge tricuspid valve repair device in China to complete large-scale clinical enrollment, and it is also one of the few such products in China with single-sheath dual-valve capability.
Leveraging the high-quality innovation capabilities of its R&D team and efficient organizational execution, Zhenyi Medical has continuously tackled key product manufacturing processes, with the entire lifecycle of the NeoBlazar® system completed by domestic enterprises. The product’s advantages in performance and price willBreaking the Monopoly of Overseas Products in Technology and Pricing, thereby promoting the high-quality development of domestically produced high-end medical devices and enabling more doctors and patients to benefit from Chinese-made high-end interventional medical devices.
Scan the QR code on the poster to add our assistant and reserve your spot for the live broadcast.
Wang Yan
President of Xiamen University Affiliated Cardiovascular Hospital
M.D., Professor, Chief Physician, and Doctoral Supervisor, The University of Hong Kong
FACC, FESC, FSCAI; National Outstanding Young and Middle-aged Expert of the National Health Commission
National Committee Member, Chinese Society of Cardiology, Chinese Medical Association
Deputy Head of the Interventional Cardiology Group, Cardiovascular Branch, Chinese Medical Association
Chairman of the Cardiovascular Professional Committee, Cross-Strait Medical Exchange Association
Vice Chairman, Structural Heart Disease Professional Committee, National Expert Committee on Cardiovascular Diseases
Vice Chairman of the Executive Committee of the Chest Pain Center of China
Vice Chairman, Chest Pain Professional Committee of the Chinese Medical Doctor Association
Vice Chairman, Cardiovascular Hypertension Branch, International Exchange and Promotion Association of Chinese Healthcare
Member, Cardiovascular Disease Expert Committee, Geriatric Medicine Committee, Chinese Society of Gerontology
Cardiovascular Disease Management Professional Committee of the China International Exchange and Promotion Association for Medical and Healthcare
Member of the Cardiovascular Physicians Branch, Chinese Medical Doctor Association
Member, Fujian Society of Cardiology, Chinese Medical Association
Member of the Chest Pain Center Committee, Thousand-County Project, Chinese Chest Pain Center Alliance
Wei Yongqiang
Chief Technology Officer, Zhenyi Medical
Ph.D. in Engineering, with over 20 years of experience in the medical health industry, possessing extensive R&D and operational expertise in high-end implantable medical devices. Previously served as the Head of R&D at a well-known listed medical device company, pioneering numerous domestic firsts in high-end implantable medical devices, and accumulating years of specialized research and management experience in the field of heart valves, making him one of China’s scarce first-generation professionals in the valve industry.
Participated in and led multiple R&D projects for Class III long-term implantable medical devices, holding over 30 invention patents and publishing several academic papers. Highly recognized by the industry for profound insight into healthcare policy environments, deep understanding of patient and customer needs, and exceptional innovative capabilities within the field.
Xu Shuhuan
Marketing Director, Zhenyi Medical
With nearly a decade of experience in the high-end medical device industry, I previously held positions at internationally renowned publicly listed medical device companies. During my tenure, I was responsible for and participated in the management and market strategic planning of multiple core projects, accumulating extensive marketing expertise and a macro-level strategic perspective on project development.
Former Regional Head at a leading Chinese interventional valve company, he witnessed the R&D and commercialization of multiple innovative products in China’s cardiovascular intervention field, drove and accelerated professional education and market promotion for these products, and is recognized as a top-tier marketing expert in China.
About Zhenyi Medical
Zhenyi Medical focuses intently on the cardiovascular disease sector, which is characterized by extremely high mortality and disability rates and remains an untapped market for domestically produced solutions in China. As the only domestic cardiovascular innovation platform enterprise specializing in addressing blood flow dynamics, the company has established a multi-tiered, multi-dimensional pipeline of cardiovascular interventional products with significant market potential across valvular heart disease, peripheral vascular disease, coronary artery disease, and heart failure. This extensively deployed pipeline demonstrates exceptional scalability.
The company adheres to a dual-path development strategy of “high cost-performance cash flow pipeline + exclusive blockbuster products in multi-billion RMB markets.” Its cash flow pipeline products benefit from mature market education and can rapidly achieve import substitution; all products have secured approvals among the first tier, meeting the clinical needs of tens of millions of patients. The exclusive blockbuster products targeting multi-billion RMB markets feature high technical barriers and address areas lacking effective treatment options. By being the only or the first in China to break technological monopolies and fill market gaps, these products swiftly capture market leadership, granting the company an extended period of market exclusivity.
To date, Zhenyi Medical has achieved remarkable progress in its dual-product-line strategy, with all products ranking among the top tier in China and demonstrating superior clinical outcomes. The company is steadily emerging as an indispensable core force in China’s cardiovascular intervention sector.
VCBeat New Product Review
“VCBeat New Product Showcase” is a live-streaming series dedicated to supporting healthcare companies in launching their innovative products. The program’s mission is to facilitate the milestone launch of every innovative medical product. Companies with plans to release innovative medical products or achieve significant milestones and wish to participate in the “VCBeat New Product Showcase” are invited to contact our assistant for more information.
Option 1: Watch the Live Stream via Mini Program
Scan the QR code below to contact the assistant and schedule a live stream (if already added, please proactively reach out to the assistant).
Method 2: Watch the live stream on the VCBeat APP, with lucky prizes waiting for you
Scan the QR code below to download the VCBeat app and register to watch the live stream.
Contact the assistant to send a screenshot of the live stream and enter the lucky draw for a chance to win a [15-day trial membership of VBInsight Industry Think Tank].
